Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schaefer M, Alt J, Gütz S, Christoph DC, Laack E, Faehling M, Fischer R, Fenchel K, Haen S, Heukamp L, Schulz C, Griesinger F.
Frost N, et al. Among authors: fenchel k.
Ther Adv Med Oncol. 2021 Feb 9;13:1758835920980558. doi: 10.1177/1758835920980558. eCollection 2021.
Ther Adv Med Oncol. 2021.
PMID: 33613692
Free PMC article.